Gobi Paramanandam, MD
Pain Medicine · Phoenix, AZNPI 1568677706
Payments from drug & device makers
Across 433 payments — averaging $6221.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2.7M
- Boston Scientific$2K
- Abbott$841
- Bard Access Systems, Inc.$674
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$581
- AbbVie$494
- plus $2K from 31 others
Across 4 payments — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
What the payments were for
- Speaking & faculty fees$25,25055%
- Travel & lodging$8,00118%
- Food & beverage$12,04926%
- Education$3341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 254 | $2,687,725 |
| Boston Scientific | 7 | $1,528 |
| Abbott | 8 | $841 |
| Bard Access Systems, Inc. | 7 | $674 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $581 |
| AbbVie(2 entities) | 26 | $494 |
| Tersera Therapeutics LLC | 10 | $346 |
| Collegium Pharmaceutical, Inc. | 22 | $283 |
| Flowonix Medical Incorporated | 1 | $224 |
| SPR Therapeutics, Inc | 3 | $188 |
| Pfizer | 9 | $146 |
| Scilex Pharmaceuticals Inc. | 7 | $135 |
| Saluda Medical Americas, Inc. | 3 | $125 |
| MML US, Inc. | 1 | $93 |
| Protega Pharmaceutials Inc | 2 | $73 |
| Nevro Corp. | 3 | $68 |
| Nalu Medical, Inc. | 2 | $46 |
| Biodelivery Sciences International, Inc. | 3 | $46 |
| Valinor Pharma, LLC | 2 | $45 |
| Virtus Pharmaceuticals LLC | 3 | $43 |
| Stryker | 1 | $43 |
| Redhill Biopharma Inc. | 2 | $39 |
| Bard Peripheral Vascular, Inc. | 1 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Sentynl Therapeutics, Inc. | 2 | $24 |
| Vertex | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Globus Medical | 1 | $23 |
| Medline Industries LP | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Amgen | 1 | $18 |
| Piramal Critical Care | 1 | $18 |
| Avanos Medical | 1 | $18 |
| Novartis | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Electronic Waveform Lab, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$27,998
- INTELLIS ADAPTIVESTIM$4,693
- KYPHON EXPRESS II KYPHOPAK TRAY$1,088
- PROCLAIM$683
- CFN PLEURX$560
- INCEPTIV$516
- Prometra II$224
- VANTA ADAPTIVESTIM$200
- SYNCHROMED$120
- PRIALT$113
- VECTRIS$105
How this compares
$2,694,111 in reported general payments places this provider in the 95th percentile of 180 pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 14 | $29,015 |
| Buprenorphine | 66 | $15,016 |
| Xtampza ErOxycodone Myristate | 23 | $14,895 |
| Fentanyl | 85 | $9,097 |
| MovantikNaloxegol Oxalate | 13 | $8,334 |
| OxycontinOxycodone Hcl | 22 | $6,827 |
| Oxycodone Hcl | 229 | $5,442 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 126 | $2,561 |
| Gabapentin | 145 | $2,280 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $1,956 |
| Morphine Sulfate ErMorphine Sulfate | 75 | $1,692 |
| Morphine Sulfate | 48 | $1,342 |
| Baclofen | 32 | $1,209 |
| Pregabalin | 59 | $1,139 |
| Tizanidine Hcl | 80 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $581 | $29,01514 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $283 | $14,89523 claims |
| Redhill Biopharma Inc.Movantik | $39 | $8,33413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 pain medicine providers in Arizona.
Other pain medicine in Phoenix
- Minesh ZaveriPhoenix$187K
- Daniel KreinerPhoenix$115K
- Christine HaddadPhoenix$98K
- Ruchir GuptaPhoenix$93K
- Omar ViswanathPhoenix$42K
- Lynn ChangPhoenix$29K
- Mark KallgrenPhoenix$24K
- Shawnjeet SainiPhoenix$14K
- Jawad ArshadPhoenix$13K
- Shafik BoyajiPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.